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Abstract
Background: VATS has become a preferred method for benign surgical conditions, yet still
remains controversial for malignancies. The purpose of this study was to review our results of
pulmonary metastasectomies using both conventional open thoracotomy and VATS techniques.
Methods: This is a retrospective chart review of pulmonary metastasectomies performed from
1986 to 2006. The surgical approach used for the initial pulmonary metastasectomy was either
open thoracotomy or VATS. Main outcomes were overall survival and recurrence free survival,
evaluated using Kaplan Meier analysis. A non-inferiority margin was set at 0.2.
Results: A total of 280 surgical procedures were performed on 186 patients. From 171 eligible
individuals, 135 patients were treated with thoracotomy (82 M, 53 F; median age 49 years), and 36
with VATS (18 M, 18 F; median age 58.5 years). Primary cancers were mainly: 81 sarcoma (47%),
26 colorectal adenocarcinoma (15%) and 22 renal cell carcinoma (13%). Median postoperative
follow was 26.2 months. The conversion rate was 10.3% and there were no cases of pleural cavity
seeding. The 5-year overall survival rates were 58.8% for thoracotomy and 69.6% for VATS, with
median overall survival of 53.2 months and 30.1 months, respectively (p = 0.03). The estimated
difference in 5-year overall survival was 10.8%. Second occurrences were noted in 59 thoracotomy
and 10 VATS patients. The 5-year recurrence free survival rates were 51% in thoracotomy and 67%
in VATS (p = 0.27), with median recurrence free survival of 24.8 months and 25.6 months,
respectively.
Conclusion: In cases of pulmonary metastases, VATS is an acceptable alternative that is both safe
and efficacious. Non-inferiority analysis of 5-year overall survival demonstrates that VATS is
equivalent to thoracotomy. VATS patients also have a longer recurrence free survival. Based on
our experience, it is permissible to use VATS resection in these circumstances: small tumor, fewer
nodules, single lesion, age ≤ 53, unilateral, tumor size amenable to wedge resection, and non-
recurrent disease.
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Background
Like other surgical specialties, thoracic surgery is moving
towards less invasive techniques. In thoracic settings, a
minimally invasive approach offers numerous benefits to
the patient. Since its introduction in the early 1990s,
video-assisted thoracoscopic surgery (VATS) has acquired
widespread favor and is currently an essential part of tho-
racic surgeon armamentarium. VATS procedures are being
used intensively to detect, diagnose and treat various
benign conditions of the lungs, pleura, diaphragm, medi-
astinum, and upper GI tract.
Despite the controversy of using VATS to treat malignan-
cies, anatomic pulmonary resection by VATS has become
a widely accepted treatment for primary lung cancers as
well as pulmonary metastases in the last decade [1]. VATS
lobectomy with lymph node dissection has already gone
well beyond the stage of an experimental technique and is
on the way to becoming a standard procedure for stage I
and II non-small cell lung cancer [2]. Although most pul-
monary metastases are discreet peripheral nodules and
can be completely removed by wedge resection, making
them the perfect candidates for VATS, some issues exist
concerning the safety of VATS – incomplete resection, port
site and pleural cavity seeding [3]. But most often, VATS is
criticized due to inability to perform thorough palpation
of the entire lung, the well-established method to detect
occult nodules missed on a conventional CT scan [4].
Although recent advancements in preoperative and intra-
operative imaging allow detection of even non-palpable
nodules [5], limited data directly comparing the oncolog-
ical soundness of thoracotomy and VATS are available. In
this study, we review our results of pulmonary metastasec-
tomies using both VATS and conventional open thoracot-
omy techniques. We compare long-term clinical
outcomes in order to determine whether or not VATS is of
disadvantage to the patient from an oncologic standpoint.
Given that the reported range of 5-year overall survival for
patients with pulmonary metastases treated with VATS or
thoracotomy varies from 30–50% among several inde-
pendent studies [6-13], we also performed a non-inferior-
ity analysis to compare the 5-year overall survival between
the standard treatment (thoracotomy) and the newer
treatment (VATS).
Methods
Eligibility Criteria
Patients with previous oncologic history were referred to
our institution for surgical management of lung metas-
tases. All patients who underwent a potentially curative
resection of pulmonary metastases, had eradication of pri-
mary tumor, and absence or effective treatment of metas-
tases at other organs – before or concurrent with
pulmonary metastasis – were identified and included in
this study. Patients were considered eligible for curative
surgery on the basis of traditional staging (chest radio-
graph, bronchoscopy, thoracic/abdominal/brain CT).
Surgeries performed for incomplete resection, biopsy-
only and/or other diagnostic purposes were excluded.
Study Design
A retrospective chart review of patients who underwent
metastasectomies from January 1986 to November 2006
was conducted using the Patient Centric Information
Management System at University of California, Los Ange-
les. This study reviews and compares the surgical treat-
ment of pulmonary metastases by either traditional open
thoracotomy or VATS. We also used a per-protocol analy-
sis to analyze non-inferiority [14].
Patients were divided into 2 groups, based on the surgical
approach used for the initial metastasectomy. Similar to
the methodology of the International Registry of Lung
Metastases, information was collected in four parts: (1)
demographics, (2) oncological features of the primary
neoplasm, (3) operative information of each metastasec-
tomy, and (4) follow-up, including relapses of primary
cancer, deaths and recurrences [15]. Maximum resection
in one operation was counted as a type of resection, even
if further wedge or segmental resections were performed.
Pulmonary lesions were detected during routine follow-
up by conventional CT scanner. The metastatic nature of
lesions was presumed, but definitive diagnosis was made
only after pathologic examination of resected specimens.
Locoregional control was assumed.
Baseline and Treatment Assessments
The primary outcome was overall survival (OS). The start
point was taken as the date of resection of first pulmonary
metastases (in cases of staged operation, the date of last
operation). The Social Security Death Index (SSDI) was
accessed for the patient status as of October 15, 2007. The
endpoint was taken as either the date of death, or either
October 15, 2007 or date of last follow-up, whichever was
later, in cases where SSDI showed that a patient was alive.
The secondary outcome was recurrence free survival
(RFS), defined as date of initial metastasectomy to date of
recurrence, instead of death. Disease free intervals (DFI)
were defined as follows: (1) DFI-1: time between primary
neoplasm and first pulmonary occurrence, (2) DFI-2: time
between first and second occurrences, and so forth (i.e.
DFI-3 to DFI-n).
To examine non-inferiority, the null hypothesis (H0) of
the present study was that the absolute difference in 5-
year survival between standard thoracotomy and VATS
exceeds the non-inferiority margin (i.e. delta) of 0.20 [16-
18]. The alternative hypothesis (Ha) was that the absolute
difference is smaller than delta. Power calculation esti-Journal of Cardiothoracic Surgery 2009, 4:13 http://www.cardiothoracicsurgery.org/content/4/1/13
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mated a total sample size of 186, based on a type I error
(α) set at 0.05, type II error (β) set at 0.2, and delta 0.20
for the difference in 5-year survival. A total of 186 patients
were recruited for this study.
Statistical Methods
All data are reported as median or frequencies, using
Mann-Whitney U test for continuous data, and Pearson χ2
test or Fisher χ2 exact for categorical data. Survival (OS and
RFS) was estimated using Kaplan-Meier analysis. Actuarial
1-, 3-, 5- and 10-year survival rates were calculated, and
corresponding survival curves were compared using the
log-rank test [19]. Log-rank test was used in univariate
analysis of prognostic influences of variables on survival.
Cox Proportional Hazards model was used in multivariate
analysis. Covariables were stepwise excluded if p > 0.2,
and included if p < 0.15. A p-value < 0.05 was considered
statistically significant [20]. All statistical manipulations
were performed using MedCalc.
Results
Patient Characteristics
A total of 280 surgical procedures were performed on 186
consecutive patients. The majority of thoracotomies were
performed from 1994–2005. We started to perform VATS
metastasectomies in 1998, and as our experience with this
approach was growing, the number of metastasectomies
performed via this approach was increasing. Eleven VATS
procedures were performed without curative intent –
biopsy, hemothorax evacuation, talc pleurodesis, or pleu-
ral debris evacuation. Adequate information was available
for the vast majority of patients. Only 15 (8%) were
excluded from the present analysis, resulting in a total of
171 individuals evaluable for the study.
At the time of initial metastasectomy, tests for homogene-
ity comparing both groups showed no statistically signifi-
cant p-values in most baseline patient and tumor
characteristics (Table 1), except in primary tumor type,
laterality of metastases, and nodal involvement. There
were noticeably more of younger patients in the OPEN
group. Sarcoma was more common in the OPEN group,
while colorectal adenocarcinoma was more common in
VATS. More tumors were unilateral and single nodular in
the VATS compared to the OPEN group. PET use began in
1998 and was used in the evaluation of 32 patients (21
OPEN, 11 VATS). Most PET evaluations were done from
2002–2005 (n = 20).
Complications
Among the 228 open surgeries performed, two patients
required intraoperative transfusion, one of which was for
disseminated intravascular coagulation. There were no
intraoperative complications in any of the 52 VATS surger-
ies. The most common postoperative complications fol-
lowing thoracotomy were arrhythmia, transfusion and
pleural effusion, whereas hydrothorax was common fol-
lowing VATS (Table 2). Atrial fibrillation was the most fre-
quent arrhythmia (6 OPEN and 1 VATS). Among those
who had thoracotomy, there was a single occurrence (<
0.5%) of each of the following postoperatively:
hematoma, pleurocutaneous fistula, respiratory distress,
post-thoracotomy syndrome, hemothorax and chylotho-
rax.
Conversion rate from VATS to thoracotomy was 10.3% (6
cases). Oncological reasons for conversion were: inability
to perform resection of a difficult nodule due to insuffi-
cient exposure (n = 5) and finding of nodule(s) not shown
on preoperative CT scan. In one patient, 1 of 2 nodules
not seen on preoperative CT was detected intraoperatively
by digital exploration. Following conversion, no addi-
tional nodules were found. Incomplete resection was seen
in one VATS patient who did not meet inclusion criteria,
and none had pleural cavity seeding.
Perioperative mortality (defined as death within 30 days
from thoracic operation) was noted in one case. Follow-
ing removal of a mucus plug by bronchoscopy, this
patient was intubated for continued respiratory distress
and required pressure support for increasing hypotension.
He had continued hypoxemia, increasing acidemia and
ultimately cardiac arrested. There were two other in-hos-
pital deaths. One patient was admitted for respiratory dis-
tress and pneumonia, and expired four days later from
respiratory failure. Another patient was admitted for
brainstem hemorrhage from a metastatic lesion in the
brainstem and cerebellum, and expired the next day from
cardiopulmonary arrest. These two patients had their last
pulmonary resection about eight months and 14 months
prior to death, respectively. At completion of this study,
74 patients were dead (four OPEN and one VATS were
thoracic deaths) and 97 alive (p = 0.88). The odds of death
in thoracotomy was 2.79 times (OR [65 × 27/9 × 70]) the
odds of death in VATS.
Tumor Response
As of January 1994, at least one thoracic recurrence was
seen in 69 patients, which were not all treated with the
same initial procedure. Second occurrences were noted in
10 VATS patients, of which 6 were treated with thoracot-
omy. In the OPEN group, 47 were treated with thoracot-
omy a second time, and two with VATS. Third occurrences
were noted in 3 VATS and 28 OPEN patients, of which 1
VATS and 25 OPEN patients were treated with thoracot-
omy. Most of the patients evaluated with PET had only
one pulmonary metastases (n = 21), whereas 6 (19%) had
two and 5 (16%) had three metastases. There is a possibil-
ity that using PET influences the outcome of patients dif-
ferently than those who were imaged with chestJournal of Cardiothoracic Surgery 2009, 4:13 http://www.cardiothoracicsurgery.org/content/4/1/13
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Table 1: Baseline patient and tumor characteristics of pulmonary metastasectomies performed from January 1986 to November 2006
All (n = 171) OPEN (n = 135) VATS (n = 36) p-value†
Age (in years)* < 0.01†
Median (Interquartile range) 53 (43–63) 49 (40–61) 58.5 (50.5–71)
95% C.I. 49 to 56 47 to 55.25 52.85 to 66.29
Sex 0.26
Female 71 (41.5) 53 (39.3) 18 (50)
Male 100 (58.5) 82 (60.7) 18 (50)
Race 0.06
Caucasian 140 (81.9) 112 (83.0) 28 (78)
non-Caucasian 31 (18.1) 23 (17) 8 (22)
Comorbidities
Single 61 (35.7) 45 (33.3) 16 (44) 0.24
3 comorbidities 10 (5.8) 5 (3.7) 5 (14) 0.04†
Smoker 62 (36.3) 47 (34.8) 15 (41.7) 0.44
Primary Tumor Type < 0.01†
Bladder 3 (1.8) 2 (1.5) 1 (3)
Breast AC 9 (5.3) 5 (3.7) 4 (11)
Colorectal AC 26 (15.2) 14 (10.4) 12 (33)
Head/Neck 4 (2.3) 3 (2.2) 1 (3)
Melanoma 14 (8.2) 6 (4.4) 8 (22)
Renal cell 22 (12.9) 21 (15.6) 1 (3)
Sarcoma 81 (47.4) 73 (54.1) 8 (22)
Testicular 5 (2.9) 5 (3.7) -
Other 7 (4.1) 6 (4.4) 1 (3)
Adjuvant therapy
Chemotherapy 129 (75.4) 106 (78.5) 23 (64) 0.08
Radiation 73 (42.7) 54 (40) 19 (53) 0.19
Laterality < 0.01†
Unilateral 124 (72.5) 90 (66.7) 34 (94)
Bilateral 47 (27.5) 45 (33.3) 2 (6)
Magnitude 0.06
Wedge resection 118 (69) 88 (65.2) 30 (83)
All other 53 (31) 47 (34.8) 6 (16.7)
Number of lesions < 0.01†
Single 48 (28.1) 28 (20.7) 20 (56)
2–5 94 (55) 79 (58.5) 15 (42)
> 5 29 (17) 28 (20.7) 1 (3)
Metastatic Occurrences 0.15
1 102 (59.6) 76 (56.3) 26 (72)
2 38 (22.2) 31 (23) 7 (19)
3+ 31 (18.1) 28 (20.7) 3 (8)
Deaths 74 (43) 65 (48) 9 (25) 0.02†
*All characteristics are expressed as no. (%), unless specified otherwise. Some covariables were grouped to preserve a 10% number of patients in 
each category for analysis. Non-Caucasian includes: Asian (10 OPEN; 7 VATS), Black (4 OPEN; 1 VATS) and Latino (9 OPEN; 0 VATS). All other 
includes: segmentectomy (17 OPEN; 4 VATS), lobectomy (29 OPEN; 2 VATS) and pneumonectomy (1 OPEN; 0 VATS). When PTT was 
categorized into carcinoma (includes bladder, breast, colorectal, melanoma, head/neck, renal cell, testicular, and 3 other type) and sarcoma 
(includes sarcoma and 3 other type), a statistical difference remained (p < 0.001). † Pearson χ2 or Fisher exact; two-tailed p-value < 0.05 considered 
statistically significant.Journal of Cardiothoracic Surgery 2009, 4:13 http://www.cardiothoracicsurgery.org/content/4/1/13
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radiograph or CT, although this was not assessed further.
Tests for homogeneity among patients with recurrence (n
= 69) showed no statistically significant difference in most
baseline patient and all baseline tumor characteristics
(Table 1). The odds of recurrence in thoracotomy was
2.02 times (OR [59 × 26/10 × 76]) the odds of recurrence
in VATS.
Time-to-Event Measures
Overall Survival
Median follow-up was shorter for VATS (30 months; 95%
C.I. 27.13 to 47.66) than for thoracotomy (57 months;
95% C.I. 46.58 to 65.15) with the longest follow-up of
191.7 months. (p = 0.01). The median OS (n = 171) was
47 months (Table 3). The actuarial 5-year OS rate was
69.6% for VATS and 58.8% for thoracotomy (Figure 1 and
Table 4); the estimated difference of 10.8% is less than
delta. The lower one-sided 95% confidence limit was -
0.036 (D - Zα × SED), which lies above the specified limit
for Δ of -0.20 [16-18].
Recurrence Free Survival
Median DFI-2 was slightly longer for those in the OPEN
group, and median RFS (n = 171) was 25 months (Table
3). Kaplan-Meier curve of RFS based on procedure is
shown in Figure 2, and actuarial rates are shown in Table
5. The RFS was better for VATS at 5- and 10-years,
although a significant difference was not seen. Most recur-
rences occurred within the first 2 years (37 OPEN, 8
VATS). Third thoracic occurrences were noted in 3 VATS
(median DFI-3: 18 months) and 28 OPEN (median DFI-
3: 11 months) patients. Fourth (n = 9, median DFI-4: 14
months), fifth (n = 3, median DFI-5: 19 months), sixth (n
= 1, DFI-6: 14 months), seventh (n = 1, DFI-7: 21 months)
and eighth (n = 1, DFI-8: 19 months) occurrences were
noted in the thoracotomy group.
Other Analyses
Univariate analysis of overall survival began with 9 poten-
tial predictors (Table 4). Age and PTT were the only pre-
dictors of OS. The 5-year OS was better in patients aged ≤
53 and in those with carcinoma. The same potential pre-
dictors were used for univariate analysis of RFS (Table 5).
Table 2: Postoperative complications for the two procedure groups, following 280 total pulmonary metastasectomies
OPEN (n = 228) VATS (n = 52)
Arrhythmia* 10 (4.4) 1 (1.9)
Pleural effusion 6 (2.6) 1 (1.9)
Transfusion 6 (2.6) -
Prolonged air leak 5 (2.2) 1 (1.9)
Pneumothorax 4 (1.8) -
Temporary vocal cord paralysis 3 (1.3) 1 (1.9)
Wound infection 3 (1.3) -
Hydrothorax 2 (0.9) 3 (5.8)
Empyema 2 (0.9) -
Post-obstructive pneumonia 2 (0.9) -
*All characteristics are expressed as no. (%)
Table 3: Time-to-event measures for the two procedure groups
All (n = 171)* OPEN (n = 135) VATS (n = 36) p-value†
DFI-1 26.5 (14.1–67.5) 27.5 (14.5–74) 24.6 (14.0–55.1) 0.79
23.54 to 33.02 23.99 to 34.4 14.26 to 40.05
OS 47.3 (24–79.6) 53.2 (23.8–89.9) 30.1 (25.2–54.7) 0.03†
38.46 to 57.97 44.73 to 64.13 27.13 to 47.66
DFI-2‡ 13.5 (7.1–31.1) 14.8 (7.2–34.3) 12.4 (5.6–13.5) 0.21
10.33 to 18.86 9.32 to 22.44 2.45 to 18.06
RFS 25.1 (10.3–57.9) 24.8 (9.8–59.9) 25.6 (12.4–45.9) 0.81
20.11 to 31.76 19.72 to 36.2 13.41 to 32.22
*First row: median (interquartile range); Second row: 95% C.I. around median.
†Two-tailed p-value < 0.05 considered statistically significant.
‡Second occurrence was seen in 59 OPEN and in 10 VATS patients.Journal of Cardiothoracic Surgery 2009, 4:13 http://www.cardiothoracicsurgery.org/content/4/1/13
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Age, PTT, laterality and magnitude were the only predic-
tors of RFS. Cox regression was then tested in all patients
of the OPEN group (control) first; age and PTT were pre-
dictors of overall survival. When all patients of the VATS
group were added and the procedures were included, age
> 53 and sarcomatous PTT remained as negative predic-
tors of OS (Table 6). Multivariate analysis of recurrence
free survival in the thoracotomy group resulted in PTT and
magnitude as predictors. When the VATS group was added
and the procedures included, sarcoma and wedge
remained as negative predictors of RFS (Table 6).
Overall survival analysis adjusted for age and RFS adjusted
for magnitude were similar to their respective unadjusted
analysis (data not shown). Overall and recurrence free
survival changed when adjusting for primary tumor type.
VATS patients with sarcoma had a better overall survival
than all patients who had carcinoma. Patients with carci-
noma had a better recurrence free survival; however, this
was higher among thoracotomy patients.
Table 4: Univariate analysis of overall survival in all 171 patients (log-rank test)
n 1-year* 3-year 5-year 10-year p-value†
Age (in years) 0.03†
≤53 88 88.6 (76) 74.2 (57) 68.8 (42) 54.1 (10)
> 53 83 88 (73) 62.8 (45) 51.7 (26) 42.8 (4)
Sex 0.31
Female 71 85.9 (60) 73.8 (45) 64.6 (31) 51.8 (9)
Male 100 90 (89) 65 (57) 57.7 (37) 44.4 (5)
Race 0.20
Caucasian 140 88.6 (124) 66.4 (81) 59.1 (55) 44.4 (11)
non-Caucasian 31 87.1 (25) 79.8 (21) 68.4 (13) 68.4 (3)
PTT 0.02†
Carcinoma 87 93.1 (79) 74.8 (58) 69.2 (41) 57.3 (7)
Sarcoma 84 83.3 (70) 62.5 (44) 51.4 (27) 39.2 (7)
DFI-1 0.79
< 1 years 34 76.5 (26) 61.1 (16) 57.3 (14) 52.9 (2)
1 to 5 years 92 90.2 (81) 70.3 (5)4 60.3 (34) 50 (7)
> 5 years 45 93.3 (42) 71.1 (32) 63.5 (20) 44.5 (5)
Laterality 0.40
Unilateral 124 91.1 (112) 72.4 (76) 63.3 (49) 46.4 (7)
Bilateral 47 80.9 (37) 58.8 (26) 53.5 (19) 49 (7)
Magnitude 0.17
Wedge 118 88.1 (102) 70 (71) 63.8 (56) 51.9 (12)
All other 53 88.7 (47) 65.8 (31) 53.7 (12) 36.9 (2)
Number of lesions 0.64
Single 48 91.7 (44) 71.8 (31) 66.9 (24) 47.8 (2)
2–5 94 89.4 (82) 68 (53) 58.5 (32) 44 (6)
> 5 29 79.3 (23) 65.5 (18) 56.4 (12) 56.4 (6)
Neoadjuvant 0.10
No 99 85.9 (84) 62.9 (55) 54.4 (36) 46.4 (7)
Yes 72 91.7 (65) 76.6 (47) 69.3 (32) 51.3 (7)
Procedure 0.24
OPEN 135 87.4 (117) 67.9 (88) 58.8 (61) 45.8 (14)
VATS 36 91.7 (32) 69.6 (14) 69.6 (7) 69.6 (0)
*All survival rates are expressed as % (number at risk), unless specified otherwise.
† Two-tailed p-value < 0.05 considered statistically significant.Journal of Cardiothoracic Surgery 2009, 4:13 http://www.cardiothoracicsurgery.org/content/4/1/13
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Discussion
Key Results
The aim of the present study was to compare long-term
clinical outcomes of the treatment of patients with pul-
monary metastases to determine whether or not VATS is
of disadvantage to the patient from an oncological stand-
point. Our results show a 5-year overall survival rate of
70% in VATS patients. Open thoracotomy was taken as a
reference treatment, with an expected survival of 50%
since prior studies have demonstrated a 5-year survival
ranging from 30–50% for the resection of pulmonary
metastases. This study showed improved long-term sur-
vival in this group of patients treated with thoracotomy
relative to previous studies [6-12], thereby supporting its
consistent efficacy in the treatment of pulmonary metas-
tases [17]. The Kaplan Meier analysis demonstrates that
survival in this group of patients is comparable to the sur-
vival expected for lung cancer operations by thoracotomy
[21].
Non-inferiority analysis suggests that the newer treatment
(VATS) is not inferior to the standard treatment (thoracot-
omy). The 10% difference in overall survival was in favor
of VATS, although this was not significantly different from
those metastasectomies done using thoracotomy. How-
ever, since the estimated 5-year survival difference in our
study of 0.108 was less than the non-inferiority margin set
at 0.20, the findings support the conclusion that the 5-
year overall survival rate using VATS is equivalent to tho-
racotomy for the treatment of pulmonary metastases.
There were also no major differences in morbidity and
mortality between both groups.
Selection of patients with the same prognosis is manda-
tory to accurately compare two therapeutic strategies. We
took this into consideration to address the possibility that
our analysis of non-inferiority is not valid given that the
36 patients in the VATS group had lesions associated with
a more favorable prognosis. The two groups of this study
were believed to be comparable in the majority of base-
Overall survival after initial metastasectomy for the two procedure groups Figure 1
Overall survival after initial metastasectomy for the two procedure groups. Median overall survival was 47.3 
months. The actuarial overall survival rates for VATS and open thoracotomy, respectively, are the following: 1-year at 91.7% 
and 87.4%; 3-year at 69.6% and 67.9%; and 5-year at 69.6% and 58.8%.
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line patient and tumor characteristics with a few excep-
tions. Univariate and multivariate analyses demonstrated
that age and primary tumor type were the only predictors
of survival; however, from the adjusted analysis, we can
infer that the imbalances in age and magnitude were not
important and the groups are comparable in these fea-
tures, and are unrelated to response to treatment. The only
predictor which may influence the response to treatment
is the primary tumor type.
Limitations
We recognize that our sample size calculation (using α of
0.01 and Δ of 0.20) was more appropriately indicative in
a per-protocol (PP) analysis, which requires fewer patients
than an intention-to-treat (ITT) analysis. Despite the mar-
ginal difference between the computed size and the eval-
uable patients, PP analysis is preferable since ITT tends to
bias towards making two treatments look similar [14]. For
future investigations, the risk of Type I error can be mini-
mized by setting α below the standard 0.05, or choosing a
smaller non-inferiority margin [17].
Table 5: Univariate analysis of recurrence free survival in all 171 patients (log-rank test)
n 1-year 3-year 5-year 10-year p-value†
Age (in years) 0.02†
≤ 53 88 73.8 (56) 55.9 (34) 44.9 (20) 37 (1)
> 53 83 88.7 (65) 68.4 (31) 62.4 (19) 55.5 (2)
Sex 0.09
Female 71 77.8 (47) 55 (25) 47.2 (15) 39.5 (2)
Male 100 83.2 (74) 67.5 (40) 57.2 (24) 48 (1)
Race 0.27
Caucasian 140 83 (102) 63.8 (54) 55.4 (33) 48.3 (3)
non-Caucasian 31 72.1 (19) 54.7 (11) 42.2 (6) 21.1 (0)
PTT < 0.001†
Carcinoma 87 94 (76) 77.4 (45) 65.4 (28) 59.1 (2)
Sarcoma 84 67.2 (45) 44.5 (20) 39.7 (11) 28.3 (1)
DFI-1 0.79
< 1 years 34 84.9 (22) 58.2 (10) 58.2 (10) 58.2 (1)
1 to 5 years 92 76.3 (62) 63 (37) 52.8 (20) 42.7 (1)
> 5 years 45 88.4 (37) 62.8 (18) 49.4 (9) 35.1 (1)
Laterality 0.03†
Unilateral 124 85.1 (96) 65.8 (51) 59.8 (31) 47.6 (1)
Bilateral 47 69.3 (25) 51.2 (14) 34.9 (8) 34.9 (2)
Magnitude 0.02†
Wedge 118 77.9 (80) 55.8 (42) 46.1 (28) 40 (2)
All other 53 87.9 (41) 76.7 (23) 76.7 (11) 54.8 (1)
Number of lesions 0.05
Single 48 91.4 (40) 69.3 (23) 62.7 (16) 51.2 (0)
2–5 94 77.9 (65) 64.6 (34) 55.6 (19) 47.3 (3)
> 5 29 72.9 (16) 40.1 (8) 27.5 (4) 27.5 (0)
Neoadjuvant 0.63
No 99 78.4 (66) 62.2 (37) 51.6 (22) 41.3 (1)
Yes 72 84.4 (55) 62.2 (28) 55 (17) 49.5 (2)
Procedure 0.27
OPEN 135 78.9 (92) 60.9 (55) 50.5 (33) 41.5 (3)
VATS 36 88.5 (29) 66.5 (10) 66.5 (6) 66.5 (0)
*All survival rates are expressed as % (number at risk), unless specified otherwise.
† Two-tailed p-value < 0.05 considered statistically significant.Journal of Cardiothoracic Surgery 2009, 4:13 http://www.cardiothoracicsurgery.org/content/4/1/13
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This study is also a retrospective investigation. A prospec-
tive randomized controlled trial on a large scale is neces-
sary to reach definitive conclusions regarding the efficacy
of VATS for the treatment of pulmonary metastases rela-
tive to other techniques. However, the possibility of
designing a three arm non-inferiority trial is limited by the
controversy of using surgical placebos. We feel that non-
inferiority of VATS over thoracotomy was effectively dem-
onstrated without the use of a placebo. In this study, VATS
was compared to an efficacious therapy [6,7,11], and
VATS was believed to be comparable to thoracotomy. This
permits basing efficacy conclusions of VATS in this study
[22]. We also recognize the possibility of bio-creep and
recommend that future trials exercise caution in the selec-
Recurrence free survival after initial metastasectomy for the two procedure groups Figure 2
Recurrence free survival after initial metastasectomy for the two procedure groups. Median recurrence free sur-
vival was 25.1 months. The actuarial recurrence free survival rates for VATS and open thoracotomy, respectively, are the fol-
lowing: 1-year at 88.5% and 78.9%; 3-year at 66.5% and 60.9%; and 5-year at 66.5% and 50.5%.
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Group: OPEN (solid line)
135 92 68 55 42 33 21 18 9 3 3
Group: VATS (broken line)
36 29 20 10 9 6 5 3 3 1 0
Table 6: Multivariate analysis of prognostic factors of overall survival and recurrence free survival (Cox Proportional Hazards)
Exp (b)* 95% C.I. p-value†
Overall Survival, all patients
Age (1: above median; 0: below median) 2.21 1.33–3.67 0.002†
PTT (1: sarcoma; 0: carcinoma) 2.65 1.57–4.46 < 0.001†
Adjuvant therapy (1: yes; 0: no) 0.69 0.43–1.12 0.14
Recurrence Free Survival, all patients
PTT (1: sarcoma; 0: carcinoma) 2.76 1.68–4.54 < 0.001†
Magnitude (1: other, 0: wedge) 0.54 0.29–0.98 0.05
*Exp (b) = Hazard Ratio
† Two-tailed p-value; < 0.05 considered statistically significant.Journal of Cardiothoracic Surgery 2009, 4:13 http://www.cardiothoracicsurgery.org/content/4/1/13
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tion of an appropriate comparator therapy and non-infe-
riority margin.
The present study may be subject to pretreatment selec-
tion bias given that group assignment was determined
through a shared decision made between physician and
patient. This can produce misleading estimates of the size
and direction of treatment effects [23]. For example, most
of the patients selected for open thoracotomy were those
with sarcoma and multiple lesions; these are associated
with higher risk, suggesting that surgeon was selecting.
Furthermore, the smaller number of patients available
who had VATS may further exaggerate the better out-
comes. Despite these possibilities, multivariate methods
were used to reduce confounding and both groups were
believed to be comparable. The increasing use of VATS
will yield more cases to evaluate in future comparative
studies over a considerable length of time.
Interpretation
The present study demonstrates a favorable outcome in 5-
year and possibly 10-year survival rates that will hopefully
contribute to VATS gaining popularity in becoming a
standard procedure. This is an interim evaluation until
further follow-up can be obtained and reported. Although
there is a difference in median follow-up, survivorship
analysis allows for estimated survival rates to be more reli-
able, even when lengths of follow-up are not equal at any
given date. The 10-year survival must be interpreted with
caution since the number of subjects at risk at this time is
small; however, the study adequately accounts for survi-
vorship in both groups for at least 6 years after the start
date.
The improved long-term survival seen in the present study
relative to previous studies could be explained by a
number of factors. The study includes patients from a sin-
gle institution with extensive experience in treating pul-
monary metastases, as well as a high volume of cases.
Improvements in our ability to detect the progression of
this disease may have occurred, as well as refinements in
surgical techniques. The 5-year survival being better for
VATS than thoracotomy could also be explained by the
possibility of completer node clearance as a result of a
clearer view and superior spread with VATS.
Altogether, among the prognostic variables tested in uni-
variate analysis age, magnitude and primary tumor type
were poor predictors of overall or recurrence free survival.
After comparing the unadjusted and adjusted survival
curves, primary tumor type remained as the only predictor
that may influence the response to treatment. Further-
more, cancers known to be associated with poorer sur-
vival, such as testicular and melanoma, were all grouped
into sarcoma. Most thoracotomy patients had sarcoma,
which could explain the relatively lower overall and recur-
rence free survival compared to VATS. Patients with carci-
noma had better overall and recurrence free survival,
except for VATS patients with sarcoma who had the high-
est overall survival.
Although age does not seem to have a prognostic influ-
ence on overall survival in previously published reports
[6,8,10,12,13,15], this study demonstrates that age > 53
had a negative influence on overall survival. This could be
explained by the fact that these patients altogether are
closer to death in the timeline of their cancer, and they
will die sooner. On the other hand, Welter and associates
found a survival advantage for elderly patients [24]. The
difference in median age at the time of initial metastasec-
tomy might be explained by the fact that younger patients
can tolerate an open procedure better-better respiratory
reserve and better health condition overall. Also, older
patients are not offered open thoracotomy simply because
they will not live long enough to benefit from the proce-
dure. In the cases of younger patients, surgeon might offer
open approach to ensure extra exploration (given the
patient can tolerate it).
Overall survival might be expected to be better in the
younger thoracotomy patients, especially since most VATS
patients were older than the median age. The survival
analysis adjusted for age showed that overall survival
remained higher in VATS patients aged > 53, although this
was not significantly different compared to the thoracot-
omy subgroup. We have not found an explanation for this
in the literature. The favorable survival in this subgroup of
VATS patients might also be explained by having more
patients with unilateral and single nodular disease.
Longer DFI seems to be a favorable prognostic factor
[7,15,24], although this study did not demonstrates DFI
as a predictor of survival. The most favorable time interval
cannot be clearly established since patients with a DFI-1 >
5 years had a better 1-, 3- and 5-year overall survival, yet a
poorer 10-year overall survival rate. We found that the
length of DFI-1 is associated with the length of DFI-2 in
only one study [7]. This study does not demonstrate this
association, and the use of VATS did not negatively impact
DFI-2. Median DFI-2 was slightly shorter in VATS,
although not statistically significant. There was no major
difference in median recurrence free survival, although
recurrences were seen less often with VATS patients, and
the recurrence free survival at 5-years was much better
than in the open thoracotomy group.
We did not take into account to location or tumor size,
but our experience leads us to believe that metastases
located in the hilar region should be treated with thora-
cotomy and larger tumors should be treated with resec-Journal of Cardiothoracic Surgery 2009, 4:13 http://www.cardiothoracicsurgery.org/content/4/1/13
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tion that optimizes complete removal. We did consider
magnitude of resection. Wedge resection was associated
with a poor RFS in univariate analysis, which was also the
case in multivariate analysis. This information may have
skewed in favor of the other procedures because this
included patients with segmentectomy, lobectomy and
pneumonectomy. Furthermore, the single patient with
pneumonectomy also had 100% OS and RFS. Lastly, since
most patients with recurrence in both groups were treated
with wedge resection, this may not have been the most
ideal resection for the patient regardless of the type of sur-
gery done.
One of the general goals of surgical oncology is complete
removal of all metastatic deposits. In the International
Registry of Lung Metastases, complete removal of all met-
astatic deposits was associated with long-term survival
[15]. The results of this study are in agreement with pub-
lished reports. Complete removal was associated with a 5-
year overall survival of 70% in VATS and 59% in thoracot-
omy. In the thoracotomy group, there was one case where
the pathology report showed some positivity at the mar-
gin, and one case with gross residual disease. Both
occurred at the time of second occurrence, and neither
had a third metastatic occurrence.
Some issues exist concerning the safety of VATS. Prior
studies have reported conversion of VATS to thoracotomy
due to incomplete fissures [25]. In this study, patients
were not converted for this reason. Other issues include
incomplete resection, and port site and pleural cavity
seeding [3]. Incomplete resection was seen in only 1 VATS
patient and this patient did not meet inclusion criteria.
There were no cases of pleural cavity seeding in this study.
There was only a single case where 1 of 2 nodules was not
shown on preoperative CT, subsequently detected intra-
operatively by digital exploration. Overall, the use of
VATS did not appear to compromise the safety of the
patients in this study.
Conclusion
This study demonstrates equivalence in morbidity and
mortality after resection of pulmonary metastases with
either open thoracotomy or VATS. Furthermore, non-infe-
riority analysis of 5-year overall survival demonstrates
that VATS is equivalent to thoracotomy. VATS patients
also have a longer recurrence free survival. Based on our
experience, we believe it is permissible to use VATS resec-
tion in these circumstances: small tumor, fewer nodules,
single lesion, age ≤ 53, unilateral, tumor size amenable to
wedge resection, and non-recurrent disease. Since this age
group altogether showed a favorable recurrence free sur-
vival but poorer overall survival, whether VATS is also per-
missible in patients aged > 53 years is something to
consider when selecting patients. Given the evidence of
this study in conjunction with prior studies that have
demonstrated the safety of VATS [21,26-28], we believe
that VATS is an acceptable alternative for resection of pul-
monary metastases that is both safe and efficacious under
the recommended circumstances.
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